Homepage

scientist working
Bakar Labs

Latest News & Upcoming Events

brad niles

Tenant Spotlight on ARIZ: Rising to the Challenge to Make Cancer Treatments More Humane 

Cancer treatments are often as grueling as the disease itself—chemotherapy can bring unbearable side effects like debilitating fatigue, nausea, and hair loss, leaving patients vulnerable and stripped of their identity. But what if cancer care could be better? More precise? Less harmful? Enter ARIZ Precision Medicine. Their mission is to revolutionize cancer care by developing therapies that not only fight the disease but also preserve the quality of life for patients. Learn how they’re doing this in our latest Tenant Spotlight. Read post
Dart hits the bullseye

ARIZ One of “Eight Nanotechnology Companies to Watch Out for”

The company’s product is composed of a nanoparticle, which is customized based on the kind of cancer it is attacking, and has small interfering RNA (siRNA) that kill proteins that drive cancer without harming the neighboring healthy cells, cancer cell targeting peptides, as well as the chemotherapy drug – which is encapsulated within the nanoparticle. The nanoparticle is PEGylated, a process by which the polymer polyethylene glycol (PEG) is added to protect the drug. Read post
The HOPO Therapeutics team in front of the Bakar Labs core facility

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

The funds will be used to advance development of the drug candidate HOPO-101 through registrational studies as a medical countermeasure against radiological threats, including planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The initial award of approximately $9.4 million will fund toxicology and pharmacology studies, manufacturing activities, and nonclinical research in other types of heavy metal poisoning, with approximately $216 million in additional funding available for later-stage development upon agreement between BARDA and HOPO. Read post
aikium

Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins

Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases. Read post
Bakar Labs in numbers
Powered by QB3

Built for startups. For more than 20 years, QB3 has been the University of California’s center for innovation and entrepreneurship in life science. Through pitch summits, seminars, symposia, podcasts, office hours, internships, and workshops QB3 educates, connects, and elevates the entrepreneurial ecosystem.

Learn about QB3
The members of Allopartis in the QB3 Garage@UCSF incubator